Skip to main content
Search

# Cell line development partnership

2 related articles

Subscribe to updates
  1. Asimov

    Asimov and Emergent sign two cell-line campaigns: CHO Edge to build high-titer research banks for two Ebola antibodies

    Asimov and Emergent BioSolutions announced a cell-line development partnership covering two full campaigns, running from vector design and synthesis through production and shipment of a high-titer research cell bank, for two monoclonal antibodies targeting Ebola. Emergent aims to obtain high-titer cell lines using Asimov's CHO Edge System, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, Asimov's AI-driven genetic design software. The work sits at the cell-line development stage, and the companies describe an intent to accelerate candidate antibody development without reporting titers or antibody results.

  2. Asimov

    Asimov and Sidewinder partner on cell line development: a 4-chain bispecific antibody reaches clonal titers above 10 g/L in a platform fed-batch process

    Asimov announced a cell line development partnership with Sidewinder Therapeutics and delivered a cell line for Sidewinder's 4-chain bispecific antibody candidate for solid tumors. Such complex molecules are hard to express, and Sidewinder needed both the required expression level and consistent product quality. Asimov ran the custom program with its CHO Edge system, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, its AI-driven genetic design software; in a platform fed-batch process the cell line achieved clonal titers of over 10 g/L.

You’re all caught up